Cancer Vaccines

Moderna and Merck Report Positive Phase 3 Topline for Personalized Melanoma Vaccine

A topline interim readout pushed Moderna shares to multiyear highs and preceded a $2.6 billion financing ahead of detailed results at the Oct. 24 ESMO presentation.